Solan Headlines

Triple Negative Breast Cancer (TNBC) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

 Breaking News
  • No posts were found

Triple Negative Breast Cancer (TNBC) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

March 24
17:45 2020
Triple Negative Breast Cancer (TNBC) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight

(Albany, US) DelveInsight has launched a new report on Triple Negative Breast Cancer Market Insights, Epidemiology and Market Forecast-2030 

DelveInsight’s “Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Triple Negative Breast Cancer, historical and forecasted epidemiology as well as the Triple Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Triple Negative Breast Cancer market report provides current treatment practices, emerging drugs, Triple Negative Breast Cancer (TNBC) market share of the individual therapies, current and forecasted Triple Negative Breast Cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Triple Negative Breast Cancer (TNBC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Triple Negative Breast Cancer is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers.

 

Request for :- Triple Negative Breast Cancer free sample page

 

Triple Negative Breast Cancer Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology division provide insights about historical and current Triple Negative Breast Cancer (TNBC) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

Report Key Facts :-

1. A study conducted by Anders et al. titled “ER/PR negative, HER2-negative (triple-negative) breast cancer,” stated that TNBC accounted for approximately 15% of breast cancers diagnosed worldwide, which amounted to almost 200,000 cases each year. Compared with hormone receptor-positive breast cancer, TNBC is more commonly diagnosed in women younger than 40 years.

2. “Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications” by Suba et al., stated that BRCA1/BRCA2 mutations are responsible for 3%–8% of all breast cancer cases, but 30–40% of familial cases. Among women with breast cancer, TNBC was established in 57.1% of BRCA1 mutation-positive and in 23.3% of BRCA2 mutation-positive cases, but in only 13.8% of BRCA– women.

 

“According to a recent news published by Brandon Scalea in a famous platform OncLive titled “TNBC Data Encouraging, But Unmet Needs Remain” stated that a better understanding of the biology of triple-negative breast cancer (TNBC) has led to the development of novel treatment approaches in a space where chemotherapy had been the sole option, but researchers are only just scratching the surface and more work needs to be done to further progress. There is a need of developing robust treatment options to fight the deadly disease i.e. mTNBC”

 

Key companies working on Triple Negative Blood Cancer that are given below:- 

1. Merck Pharmaceutical Co. 

2. Hoffmann-La Roche Pharma Co.

 

Name of drugs covered are given below;- 

1.  Pembrolizumab

2. Ipatasertib

 

Table of Content

1. Key Insights

2. Executive Summary of Triple Negative Breast Cancer (TNBC)

3. Competitive Intelligence Analysis for Triple Negative Breast Cancer (TNBC)

4. Triple Negative Breast Cancer (TNBC): Market Overview at a Glance

4.1. Triple Negative Breast Cancer (TNBC) Total Market Share (%) Distribution in 2017

4.2. Triple Negative Breast Cancer (TNBC) Total Market Share (%) Distribution in 2030

5. Triple Negative Breast Cancer (TNBC): Disease Background and Overview 

6. Patient Journey

7. Triple Negative Breast Cancer (TNBC) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Triple Negative Breast Cancer (TNBC) Treatment and Management

8.2. Triple Negative Breast Cancer (TNBC) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Triple Negative Breast Cancer (TNBC) Treatment

11. Marketed Products

12. Emerging Therapies

13. Triple Negative Breast Cancer (TNBC): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Triple Negative Breast Cancer (TNBC)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

 

Why should you buy this report ?

  • The report will help in developing business strategies by understanding trends shaping and driving the Triple Negative Breast Cancer (TNBC) market
  • To understand the future market competition in the Triple Negative Breast Cancer (TNBC) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Triple Negative Breast Cancer (TNBC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Triple Negative Breast Cancer (TNBC) market
  • To understand the future market competition in the Triple Negative Breast Cancer (TNBC) market

 

Related Reports:- 

1. Triple Negative Breast Cancer (TNBC) – Epidemiology Forecast to 2030

2. Triple Negative Breast Neoplasms Market Insight, Epidemiology and Market Forecast -2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles